Advertisement

Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC)

Published:September 28, 2017DOI:https://doi.org/10.1016/j.ejca.2017.07.039

      Abstract

      Quality assurance (QA) programmes are one of the mainstays of clinical research and constitute the pillars on which European Organisation for Research Treatment of Cancer (EORTC) delivers multidisciplinary therapeutic progress. Changing practice treatments require solid evidence-based data, which can only be achieved if integral QA is part of the infrastructure sustaining research projects. Cancer treatment is a multimodality approach, which is often applied either in sequence and/or in combination. Each modality plays a key role in cancer control. The modalities by which QA is applied varies substantially within and across the disciplines. In addition, translational and diagnostic disciplines take an increasing role in the era of precision medicine. Building on the structuring effect of clinical research with fully integrated multidisciplinary QA programmes associated with the solutions addressing the chain of custody for biological material and data integrity as well as compliance ensure at the same time validity of clinical research output but also have a training effect on health care providers, who are more likely to apply such principles as routine. The principles of QA are therefore critical to be embedded in multidisciplinary infrastructure to guarantee therapeutic progress. These principles also provide the basis for the functioning of multidisciplinary tumour board. However, technical, operational and economic challenges which go with the implementation of such programmes require optimal know-how and the coordination of the multiple expertise and such efforts are best achieved through centralised infrastructure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ottevanger P.B.
        • Therasse P.
        • Van De Velde C.
        • Bernier J.
        • Van Krieken H.
        • Grol R.
        • et al.
        Quality assurance in clinical trials.
        Crit Rev Oncol Hematol. 2003; 47: 213-235https://doi.org/10.1016/S1040-8428(03)00028-3
        • Vantongelen K.
        • Steward W.
        • Blackledge G.
        • Verweij J.
        • Van Oosterom A.
        EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials.
        Eur J Cancer Clin Oncol. 1991; 27: 201-207https://doi.org/10.1016/0277-5379(91)90488-Y
        • Tudur Smith C.
        • Stocken D.D.
        • Dunn J.
        • Cox T.
        • Ghaneh P.
        • Cunningham D.
        • et al.
        The value of source data verification in a cancer clinical trial.
        PLoS One. 2012; 7https://doi.org/10.1371/journal.pone.0051623
        • Favalli G.
        • Vermorken J.B.
        • Vantongelen K.
        • Renard J.
        • Van Oosterom A.T.
        • Pecorelli S.
        Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group.
        Eur J Cancer. 2000; 36: 1125-1133https://doi.org/10.1016/S0959-8049(00)00090-3
        • Weiss R.B.
        • Vogelzang N.J.
        • Peterson B.A.
        • Panasci L.C.
        • Carpenter J.T.
        • Gavigan M.
        • et al.
        A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.
        JAMA. 1993; 270: 459-464
        • Tanis E.
        • Caballero C.
        • Collette L.
        • Verleye L.
        • den Dulk M.
        • Lacombe D.
        • et al.
        The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: assessment of the past and moving towards the future.
        Eur J Surg Oncol. 2016; 42: 1115-1122https://doi.org/10.1016/j.ejso.2016.04.052
        • Landheer M.L.
        • Therasse P.
        • van de Velde C.J.
        Quality assurance in surgical oncology (QASO) within the European Organization for Research and Treatment of Cancer (EORTC): current status and future prospects.
        Eur J Cancer. 2001; 37 (S0959-8049(01)00157-5 [pii]): 1450-1462
        • den Dulk M.
        • Collette L.
        • van de Velde C.J.H.
        • Marijnen C.A.M.
        • Calais G.
        • Mineur L.
        • et al.
        Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921.
        Eur J Cancer. 2007; 43: 1821-1828https://doi.org/10.1016/j.ejca.2007.05.025
        • Kapiteijn E.
        • Klein Kranenbarg W.E.
        • Kranenbarg E.K.
        • Steup W.H.
        • Taat C.W.
        • Rutten H.J.
        • et al.
        Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer: prospective randomised trial with standard operative and histopathological techniques.
        Eur J Surg. 1999; 165: 410-420https://doi.org/10.1080/110241599750006613
        • Donker M.
        • van Tienhoven G.
        • Straver M.E.
        • Meijnen P.
        • van de Velde C.J.H.
        • Mansel R.E.
        • et al.
        Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): arandomised, multicentre, open-label, phase 3 non-inferiority trial.
        Lancet Oncol. 2014; 15: 1303-1310https://doi.org/10.1016/S1470-2045(14)70460-7
        • den Dulk M.
        • Krijnen P.
        • Marijnen C.A.M.
        • Rutten H.J.
        • van de Poll-Franse L.V.
        • Putter H.
        • et al.
        Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy.
        Eur J Cancer. 2008; 44: 1710-1716https://doi.org/10.1016/j.ejca.2008.05.004
        • Peeters K.C.M.J.
        • Marijnen C.A.M.
        • Nagtegaal I.D.
        • Kranenbarg E.K.
        • Putter H.
        • Wiggers T.
        • et al.
        The TME trial after a median follow-up of 6 years.
        Ann Surg. 2007; 246: 693-701https://doi.org/10.1097/01.sla.0000257358.56863.ce
        • van Gijn W.
        • Krijnen P.
        • Lemmens V.E.P.P.
        • den Dulk M.
        • Putter H.
        • van de Velde C.J.H.
        Quality assurance in rectal cancer treatment in The Netherlands: a catch up compared to colon cancer treatment.
        Eur J Surg Oncol. 2010; 36: 340-344https://doi.org/10.1016/j.ejso.2009.10.010
        • Size S.
        Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial.
        N Engl J Med. 1997; 336: 980-987https://doi.org/10.1056/NEJM199704033361402
        • Dindo D.
        • Demartines N.
        • Clavien P.-A.
        Classification of surgical complications. A newproposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213https://doi.org/10.1097/01.sla.0000133083.54934.ae
        • Evrard S.
        • Audisio R.
        • Poston G.
        • Caballero C.
        • Kataoka K.
        • Fontein D.
        • et al.
        From a comic opera to surcare an open letter to whom clinical research in surgery is a concern: announcing the launch of SURCARE.
        Ann Surg. 2016; 264: 911-912https://doi.org/10.1097/SLA.0000000000001700
        • Evrard S.
        • McKelvie-Sebileau P.
        • van de Velde C.
        • Nordlinger B.
        • Poston G.
        What can we learn from oncology surgical trials?.
        Nat Rev Clin Oncol. 2015; 13: 55-62https://doi.org/10.1038/nrclinonc.2015.176
        • Wagner A.D.
        • Kang Y.K.
        • Van Dieren J.
        • Mauer M.
        • Grabsch H.
        • Caballero C.
        • et al.
        64. EORTC-1203: integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047.
        Eur J Surg Oncol. 2016; 42: S91-S92https://doi.org/10.1016/j.ejso.2016.06.070
        • Caballero C.I.
        • Carrion Alvarez L.
        • Rivoire M.
        • Nilsson H.
        • Staettner S.
        • Gruenberger T.
        • et al.
        80. EORTC-1409: an EORTC-ESSO prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB) NCT02218801.
        Eur J Surg Oncol. 2016; 42: S99https://doi.org/10.1016/j.ejso.2016.06.086
        • Weber D.C.
        • Poortmans P.M.P.
        • Hurkmans C.W.
        • Aird E.
        • Gulyban A.
        • Fairchild A.
        Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting.
        Radiother Oncol. 2011; 100: 150-156https://doi.org/10.1016/j.radonc.2011.05.073
        • Neoptolemos J.P.
        • Stocken D.D.
        • Friess H.
        • Bassi C.
        • Dunn J.A.
        • Hickey H.
        • et al.
        A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
        N Engl J Med. 2004; 350: 1200-1210https://doi.org/10.1056/NEJMoa032295
        • Koshy M.C.
        • Landry J.C.
        • Cavanaugh S.X.
        • Fuller C.D.
        • Willett C.G.
        • Abrams R.A.
        • et al.
        A challenge to the therapeutic nihilism of ESPAC-1.
        Int J Radiat Oncol. 2005; 61: 965-966https://doi.org/10.1016/j.ijrobp.2004.11.018
        • Weber D.C.
        • Tomsej M.
        • Melidis C.
        • Hurkmans C.W.
        QA makes a clinical trial stronger: evidence-based medicine in radiation therapy.
        Radiother Oncol. 2012; 105: 4-8https://doi.org/10.1016/j.radonc.2012.08.008
        • Rischin D.
        • Peters L.J.
        • O'Sullivan B.
        • Giralt J.
        • Fisher R.
        • Yuen K.
        • et al.
        Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
        J Clin Oncol. 2010; 28: 2989-2995https://doi.org/10.1200/JCO.2009.27.4449
        • Peters L.J.
        • O'Sullivan B.
        • Giralt J.
        • Fitzgerald T.J.
        • Trotti A.
        • Bernier J.
        • et al.
        Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.
        J Clin Oncol. 2010; 28: 2996-3001https://doi.org/10.1200/JCO.2009.27.4498
        • Horiot J.C.
        • Johansson K.A.
        • Gonzalez D.G.
        • van der Schueren E.
        • van den Bogaert W.
        • Notter G.
        Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment.
        Radiother Oncol. 1986; 6: 275-284https://doi.org/10.1016/S0167-8140(86)80194-3
        • Fairchild A.
        • Aird E.
        • Fenton P.A.
        • Gregoire V.
        • Gulyban A.
        • Lacombe D.
        • et al.
        EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility.
        Radiother Oncol. 2012; 103: 279-286https://doi.org/10.1016/j.radonc.2012.04.015
        • Fairchild A.
        • Bar-Deroma R.
        • Collette L.
        • Haustermans K.
        • Hurkmans C.
        • Lacombe D.
        • et al.
        Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach.
        Eur J Cancer. 2012; 48: 1048-1054https://doi.org/10.1016/j.ejca.2012.02.008
        • Fairchild A.
        • Collette L.
        • Hurkmans C.W.
        • Baumert B.
        • Weber D.C.
        • Gulyban A.
        • et al.
        Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?.
        Eur J Cancer. 2012; 48: 3232-3239https://doi.org/10.1016/j.ejca.2012.06.002
        • Fairchild A.
        • Weber D.C.
        • Bar-Deroma R.
        • Gulyban A.
        • Fenton P.A.
        • Stupp R.
        • et al.
        Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
        Radiother Oncol. 2012; 103: 287-292https://doi.org/10.1016/j.radonc.2012.04.002
        • Matzinger O.
        • Poortmans P.
        • Giraud J.Y.
        • Maingon P.
        • Budiharto T.
        • van den Bergh A.C.M.
        • et al.
        Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
        Radiother Oncol. 2009; 90: 285-290https://doi.org/10.1016/j.radonc.2008.10.022
        • Grant W.
        • Hurkmans C.W.
        • Poortmans P.M.
        • Maingon P.
        • Monti A.F.
        • Van Os M.J.H.
        • et al.
        Quality assurance standards drive improvements in the profile of radiation therapy departments participating in trials of the EORTC Radiation Oncology Group.
        Radiother Oncol. 2014; 112: 376-380https://doi.org/10.1016/j.radonc.2014.09.003
        • Coskun M.
        • Straube W.
        • Hurkmans C.W.
        • Melidis C.
        • de Haan P.F.
        • Villà S.
        • et al.
        Quality assurance of radiotherapy in the ongoing {EORTC} 22042-26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case {Reviews}.
        Radiat Oncol. 2013; 8: 23https://doi.org/10.1186/1748-717X-8-23
        • Lambrecht M.
        • Melidis C.
        • Sonke J.-J.
        • Adebahr S.
        • Boellaard R.
        • Verheij M.
        • et al.
        Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours– a clinical physics perspective.
        Radiat Oncol. 2016; 11: 7https://doi.org/10.1186/s13014-015-0567-5
        • Ibbott G.S.
        • Followill D.S.
        • Molineu H.A.
        • Lowenstein J.R.
        • Alvarez P.E.
        • Roll J.E.
        Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials.
        Int J Radiat Oncol Biol Phys. 2008; 71https://doi.org/10.1016/j.ijrobp.2007.08.083
        • Melidis C.
        • Bosch W.R.
        • Izewska J.
        • Fidarova E.
        • Zubizarreta E.
        • Ulin K.
        • et al.
        Global harmonization of quality assurance naming conventions in radiation therapy clinical trials.
        Int J Radiat Oncol Biol Phys. 2014; 90: 1242-1249https://doi.org/10.1016/j.ijrobp.2014.08.348
        • Fitzgerald T.J.
        • Bishop-Jodoin M.
        • Bosch W.R.
        • Curran W.J.
        • Followill D.S.
        • Galvin J.M.
        • et al.
        Future vision for the quality assurance of oncology clinical trials.
        Front Oncol. 2013; 3: 31https://doi.org/10.3389/fonc.2013.00031
        • Verweij J.
        • Nielsen O.S.
        • Therasse P.
        • van Oosterom A.T.
        The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC soft tissue and bone sarcoma group.
        Eur J Cancer. 1997; 33: 1045-1049https://doi.org/10.1016/S0959-8049(97)00027-0
        • Lasnon C.
        • Salomon T.
        • Desmonts C.
        • D?? P.
        • Oulkhouir Y.
        • Madelaine J.
        • et al.
        Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
        Ann Nucl Med. 2017; 31: 125-134https://doi.org/10.1007/s12149-016-1135-2
        • Hristova I.
        • Boellaard R.
        • Vogel W.
        • Mottaghy F.
        • Marreaud S.
        • Collette S.
        • et al.
        Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial.
        Eur J Nucl Med Mol Imaging. 2015; 42: 848-857https://doi.org/10.1007/s00259-015-3002-0
        • Betsou F.
        Biospecimen processing method validation.
        Biopreserv Biobank. 2015; 13 (69–69)https://doi.org/10.1089/bio.2015.1321
        • Lehmann S.
        • Guadagni F.
        • Moore H.
        • Ashton G.
        • Barnes M.
        • Benson E.
        • et al.
        Standard preanalyticalcoding for biospecimens: review and implementation of the sample PRE analytical code (SPREC).
        Biopreserv Biobank. 2012; 10: 366-374https://doi.org/10.1089/bio.2012.0012
        • Betsou F.
        • Bulla A.
        • Cho S.Y.
        • Clements J.
        • Chuaqui R.
        • Coppola D.
        • et al.
        Assays for qualification and quality stratification of clinical biospecimens used in research: a technical report from the ISBER biospecimen science working group.
        Biopreserv Biobank. 2016; 14: 398-409https://doi.org/10.1089/bio.2016.0018
        • Gaignaux A.
        • Ashton G.
        • Coppola D.
        • De Souza Y.
        • De Wilde A.
        • Eliason J.
        • et al.
        A biospecimen proficiency testing program for biobank accreditation: four years of experience.
        Biopreserv Biobank. 2016; 14: 429-439https://doi.org/10.1089/bio.2015.0108
        • Naredi P.
        • Quaglia MP La
        The future of trials in surgical oncology.
        Nat Rev Clin Oncol. 2015; 12